Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): Results from a phase II randomized discontinuation trial (RDT).
Allen Lee Cohn
No relevant relationships to disclose
Robin Katie Kelley
No relevant relationships to disclose
Tsai-Shen Yang
No relevant relationships to disclose
Wu-Chou Su
No relevant relationships to disclose
Chris Verslype
No relevant relationships to disclose
David A. Ramies
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Yihua Lee
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Xiaodong Shen
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Eric Van Cutsem
No relevant relationships to disclose